SPY433.24-9.40 -2.12%
DIA342.73-5.88 -1.69%
IXIC14,552.98-416.99 -2.79%

Immutep Completes Recruitment, Dosing in Phase 2 Trial of Non-Small Cell Lung Cancer Combo Therapy

MT Newswires · 09/01/2021 01:04

Please log in to view news